{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:24:51Z","timestamp":1791289491353,"version":"4.3.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of metastatic melanoma. Several case reports have documented IgG4-related disease (IgG4-RD) as an adverse event following ICI therapy. Here we report the first instance of interstitial nephritis associated with IgG4-RD as an immune-related adverse event (irAE) following ICI treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 71-year-old male with malignant melanoma (BRAF wild-type) initially received one cycle of adjuvant pembrolizumab, followed by four cycles of ipilimumab\/nivolumab after the occurrence of lung metastases. Four months later, a follow-up computed tomography (CT) revealed infiltrative masses in the kidneys, along with abnormal mediastinal and hilar lymphadenopathy but his baseline serum creatinine remained stable. A subsequent kidney biopsy showed renal parenchyma with significant interstitial nephritis and an increase in IgG4-positive plasma cells, with no evidence of malignancy. Plasma IgG4 levels were elevated at 294\u00a0mg\/dL (normal 11\u2013157\u00a0mg\/dL), and complement C4 level was low at &lt;\u20098\u00a0mg\/dL. In addition, the patient had an asymptomatic rise in lipase (105 U\/L, normal 7\u201360 U\/L), but had no other findings to suggest pancreatitis. The patient was started on prednisone 40\u00a0mg daily with a plan to taper. A follow-up CT scan performed four weeks later showed near-complete resolution of the previously observed mediastinal lymphadenopathy and bilateral infiltrative renal masses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This represents the first reported case of interstitial nephritis resulting from IgG4-related disease following ICI treatment. Clinicians should consider the potential for IgG4-RD, particularly with associated renal manifestations, in patients undergoing ICI therapy. Early recognition and treatment of this rare side effect can significantly impact the clinical outcome. This case highlights the importance of being vigilant for uncommon and new adverse effects following ICI treatment, especially as the field continues to evolve and new immunotherapies are developed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41927-025-00548-1","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:53:13Z","timestamp":1754027593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IgG4-related disease with interstitial nephritis in a patient with metastatic melanoma following immune checkpoint inhibitor treatment: a case report"],"prefix":"10.1186","volume":"9","author":[{"given":"Thabuna","family":"Sivaprakasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachaya","family":"Nitchaikulvatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Gedallovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagruti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Charles","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"4","key":"548_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, et al. Adverse effects of immune checkpoint inhibitors (Programmed Death-1 inhibitors and cytotoxic T-Lymphocyte-Associated Protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019;11(4):225\u201336. https:\/\/doi.org\/10.14740\/jocmr3750.","journal-title":"J Clin Med Res"},{"key":"548_CR2","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"MA Hossain","year":"2024","unstructured":"Hossain MA. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143:113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365.","journal-title":"Int Immunopharmacol"},{"key":"548_CR3","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","journal-title":"Front Immunol"},{"issue":"1","key":"548_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire J, et al. The 2019 American college of rheumatology\/european league against rheumatism classification criteria for IgG4\u2010related disease. Arthritis Rheumatol. 2019;72(1):7\u201319. https:\/\/doi.org\/10.1002\/art.41120.","journal-title":"Arthritis Rheumatol"},{"key":"548_CR5","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3591-24","author":"S Inoue","year":"2024","unstructured":"Inoue S, Tsunoda Y, Yamamoto K, Okamoto H. Immunoglobulin G4-related autoimmune pancreatitis and hypopituitarism following immune checkpoint inhibitor therapy: a case report. Intern Med 2024. https:\/\/doi.org\/10.2169\/internalmedicine.3591-24.","journal-title":"Intern Med"},{"issue":"1","key":"548_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/1759-7714.15155","volume":"15","author":"M Nishimura","year":"2023","unstructured":"Nishimura M, Kimizuka Y, Ogawa T, Tsuchiya M, Kato Y, Matsukida A, et al. IgG4-related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non-small cell lung cancer: a case report. Thorac Cancer. 2023;15(1):104\u20137. https:\/\/doi.org\/10.1111\/1759-7714.15155","journal-title":"Thorac Cancer"},{"issue":"20","key":"548_CR7","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.12998\/wjcc.v10.i20.7124","volume":"10","author":"R Agrawal","year":"2022","unstructured":"Agrawal R, Guzman G, Karimi S, Giulianotti PC, Lora AJM, Jain S, et al. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: a case report. World J Clin Cases. 2022;10(20):7124\u20139. https:\/\/doi.org\/10.12998\/wjcc.v10.i20.7124.","journal-title":"World J Clin Cases"},{"issue":"6","key":"548_CR8","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/cancers15061891","volume":"15","author":"E Longhitano","year":"2023","unstructured":"Longhitano E, Muscolino P, Lo Re C, Ferrara SA, Cernaro V, Gembillo G, et al. Immune checkpoint inhibitors and the kidney: a focus on diagnosis and management for personalised medicine. Cancers. 2023;15(6):1891. https:\/\/doi.org\/10.3390\/cancers15061891.","journal-title":"Cancers"},{"issue":"8","key":"548_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11886-021-01530-2","volume":"23","author":"DJ Lee","year":"2021","unstructured":"Lee DJ, Lee HJ, Farmer JR, Reynolds KL. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 2021;23(8):87. https:\/\/doi.org\/10.1007\/s11886-021-01530-2.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"548_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","volume":"41","author":"N Murakami","year":"2016","unstructured":"Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint Blockade. Curr Probl Cancer. 2016;41(2):100\u201310. https:\/\/doi.org\/10.1016\/j.currproblcancer.2016.12.004.","journal-title":"Curr Probl Cancer"},{"issue":"10","key":"548_CR11","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","volume":"9","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(10):e003467. https:\/\/doi.org\/10.1136\/jitc-2021-003467.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"548_CR12","doi-asserted-by":"publisher","first-page":"rkad020","DOI":"10.1093\/rap\/rkae020","volume":"8","author":"ZS Wallace","year":"2024","unstructured":"Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract. 2024;8(2):rkad020. https:\/\/doi.org\/10.1093\/rap\/rkae020.","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"548_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pathol.2022.04.010","volume":"55","author":"B Champion","year":"2022","unstructured":"Champion B, Chai SM, Bhandari M, Gunawardena D. IgG4-related autoimmune pancreatitis-like mass-forming lesion on a background of immune checkpoint inhibitor immunotherapy. Pathology. 2022;55(1):133\u20136. https:\/\/doi.org\/10.1016\/j.pathol.2022.04.010.","journal-title":"Pathology"},{"issue":"1","key":"548_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-020-1150-x","volume":"20","author":"T Terashima","year":"2020","unstructured":"Terashima T, Iwami E, Shimada T, Kuroda A, Matsuzaki T, Nakajima T, et al. IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report. BMC Pulm Med. 2020;20(1):1\u20135. https:\/\/doi.org\/10.1186\/s12890-020-1150-x.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"548_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5527\/wjn.v7.i1.29","volume":"7","author":"M Salvadori","year":"2018","unstructured":"Salvadori M, Tsalouchos A. Immunoglobulin G4-related kidney diseases: an updated review. World J Nephrol. 2018;7(1):29\u201340. https:\/\/doi.org\/10.5527\/wjn.v7.i1.29.","journal-title":"World J Nephrol"},{"issue":"11","key":"548_CR16","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3899\/jrheum.150436","volume":"42","author":"J Asano","year":"2015","unstructured":"Asano J, Watanabe T, Oguchi T, Kanai K, Maruyama M, Ito T, et al. Association between Immunoglobulin G4-related disease and malignancy within 12 years after diagnosis: an analysis after longterm followup. J Rheumatol. 2015;42(11):2135\u201342. https:\/\/doi.org\/10.3899\/jrheum.150436.","journal-title":"J Rheumatol"},{"key":"548_CR17","doi-asserted-by":"publisher","first-page":"1043874","DOI":"10.3389\/fneph.2023.1043874","volume":"3","author":"R Fenoglio","year":"2023","unstructured":"Fenoglio R, Cozzi M, Del Vecchio G, Sciascia S, Barreca A, Comandone A, et al. The need for kidney biopsy in the management of side effects of target and immunotherapy. Front Nephrol. 2023;3:1043874. https:\/\/doi.org\/10.3389\/fneph.2023.1043874.","journal-title":"Front Nephrol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00548-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T01:05:21Z","timestamp":1754355921000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00548-1","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient has given written informed consent for publishing the personal, clinical details and associated images in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}